FDA Inspection 1276175 — Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
The FDA completed an inspection of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on Jun 13, 2025 in Shenzhen. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Jun 13, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Shenzhen (China)